Rite Aid ex-execs
This article was originally published in The Tan Sheet
Executive Summary
Former VP Eric Sorkin pleads guilty June 26 in Harrisburg, Penn. federal court to single charge of conspiracy. He faces maximum five-year prison sentence and fine of up to $250,000. Franklin Brown, drugstore chain's former chief counsel, granted postponement until July 14 to decide whether he will plead guilty or go to trial. Actions follow ex-Rite Aid CEO Martin Grass' guilty plea to one count of conspiracy to obstruct justice, one count of conspiracy to defraud Rite Aid and its shareholders June 17. The 49-year old exec faces more than $3.5 mil. in monetary penalties, eight-year prison sentence under plea agreement. Grass and Sorkin could testify against Brown. Justice Department filed criminal charges, SEC filed account fraud charges against Rite Aid last June (1"The Tan Sheet" July 8, 2002, In Brief)...
You may also be interested in...
Rite Aid indictments
Leiner Health Products, Warner Lambert Consumer Healthcare (now part of Pfizer) among vendors defrauded in wide-ranging scheme by former and current Rite Aid executives to materially overstate the drug store chain's income between May 1997 and May 1999, federal prosecutors allege in recent indictments against the executives. Vendors were subject to "systematically inflated" charges for damaged, outdated merchandise (totaling $28 mil. in FY 1999) and/or "bogus" charges for items purportedly sold at clearance ($30 mil. in 1999). Indictment cites February 1999 invoices to Warner Lambert for $539,000 and Leiner for $508,000 as evidence of fraud conspiracy and mail fraud. Justice Department criminal charges and SEC accounting fraud charges against Rite Aid were filed June 21 in Harrisburg, Penn. federal court...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately-owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.